315 related articles for article (PubMed ID: 7930273)
1. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Reiner JS; Lundergan CF; van den Brand M; Boland J; Thompson MA; Machecourt J; Py A; Pilcher GS; Fink CA; Burton JR
J Am Coll Cardiol; 1994 Nov; 24(6):1439-44. PubMed ID: 7930273
[TBL] [Abstract][Full Text] [Related]
2. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Gibson CM; Cannon CP; Piana RN; Breall JA; Sharaf B; Flatley M; Alexander B; Diver DJ; McCabe CH; Flaker GC
J Am Coll Cardiol; 1995 Mar; 25(3):582-9. PubMed ID: 7860900
[TBL] [Abstract][Full Text] [Related]
3. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
[TBL] [Abstract][Full Text] [Related]
4. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
5. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.
Singh N; Mironov D; Armstrong PW; Ross AM; Langer A
Circulation; 1996 Apr; 93(7):1388-95. PubMed ID: 8641028
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Langer A; Krucoff MW; Klootwijk P; Veldkamp R; Simoons ML; Granger C; Califf RM; Armstrong PW
J Am Coll Cardiol; 1995 Jun; 25(7):1552-7. PubMed ID: 7759706
[TBL] [Abstract][Full Text] [Related]
7. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Lundergan CF; Reiner JS; McCarthy WF; Coyne KS; Califf RM; Ross AM
J Am Coll Cardiol; 1998 Sep; 32(3):641-7. PubMed ID: 9741505
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
10. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
11. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
[TBL] [Abstract][Full Text] [Related]
12. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.
Woodfield SL; Lundergan CF; Reiner JS; Greenhouse SW; Thompson MA; Rohrbeck SC; Deychak Y; Simoons ML; Califf RM; Topol EJ; Ross AM
J Am Coll Cardiol; 1996 Dec; 28(7):1661-9. PubMed ID: 8962549
[TBL] [Abstract][Full Text] [Related]
13. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
[TBL] [Abstract][Full Text] [Related]
14. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
Bates ER
Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
[TBL] [Abstract][Full Text] [Related]
15. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.
Barbagelata NA; Granger CB; Oqueli E; Suárez LD; Borruel M; Topol EJ; Califf RM
Am Heart J; 1997 Mar; 133(3):273-82. PubMed ID: 9060794
[TBL] [Abstract][Full Text] [Related]
16. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
GUSTO investigators
N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
[TBL] [Abstract][Full Text] [Related]
18. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
19. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
Holmes DR; Califf RM; Topol EJ
J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):10S-17S. PubMed ID: 7775708
[TBL] [Abstract][Full Text] [Related]
20. Gender and acute myocardial infarction: is there a different response to thrombolysis?
Woodfield SL; Lundergan CF; Reiner JS; Thompson MA; Rohrbeck SC; Deychak Y; Smith JO; Burton JR; McCarthy WF; Califf RM; White HD; Weaver WD; Topol EJ; Ross AM
J Am Coll Cardiol; 1997 Jan; 29(1):35-42. PubMed ID: 8996292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
